BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-159@catalystbrief.girapphe.com
DTSTAMP:20261118T181604Z
LAST-MODIFIED:20261118T181604Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Readout: Han Xu\, M.D.\, Ph.D.\, FAPCR\, Medical Director\, IRB Cha
 ir — Topotecan - usual [Dec 2026]
DESCRIPTION:Phase 3 primary completion: Pharmacogenomics ANDA SNP Clinical 
 Study - Topotecan and Single Nucleotide Polymorphisms.\nSource: https://cl
 inicaltrials.gov/study/NCT07145333\nhttps://catalystbrief.girapphe.com/e/1
 59?lang=en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/159?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
